Single-Centre Experience of Systemic Treatment with Vincristine, Ifosfamide, and Doxorubicin Alternating with Etoposide, Ifosfamide, and Cisplatin in Adult Patients with Ewing Sarcoma

<div>(a) Radiological response evaluation after 2 cycles of VIA and (b) radiological response evaluation after 2 cycles of VIA and 2 cycles of VIP according to RECIST 1.1. SD: stable disease; PR: partial response; CR: complete response; N/a: nonevaluable; RECIST: Response Evaluation Criteria in Solid Tumors; VIA: vincristine, ifosfamide, and doxorubicin; VIP: etoposide, ifosfamide, and cisplatin.</div>

Sarcoma

fig4

Figure 4

Figure 4: Single-Centre Experience of Systemic Treatment with Vincristine, Ifosfamide, and Doxorubicin Alternating with Etoposide, Ifosfamide, and Cisplatin in Adult Patients with Ewing Sarcoma 

Figure 4 | Single-Centre Experience of Systemic Treatment with Vincristine, Ifosfamide, and Doxorubicin Alternating with Etoposide, Ifosfamide, and Cisplatin in Adult Patients with Ewing Sarcoma 